FloodLAMP FDA October 2021 Correspondence Analysis Analysis of FloodLAMP's October 2021 FDA correspondence -- the concentrated sequence of emails, deficiency letter, Zoom meeting (with Anne Wyllie), FloodLAMP's response, and FDA's final deprioritization/closure of EUA210582 for the QuickColor COVID-19 Test. Presents a complete timeline from October 2020 through October 2021, identifies FDA's stated justifications (clinical data gaps, resource triage, deprioritization policy), and offers five interpretive explanations of the FDA's rationale ranging from legitimate resource constraints to structural bias against small/novel entrants, with attention to the Omicron-wave irony five weeks later. ai file regulatory fl-fda-correspondence _AI_FloodLAMP FDA October 2021 Correspondence Analysis.md regulatory/fl-fda-correspondence/_AI_FloodLAMP FDA October 2021 Correspondence Analysis.md 2026_03_02 Created by Claude Opus 4.6 Max and ChatGPT 5.2 Pro Extended during archive preparation. **NOT HUMAN VERIFIED - MAY CONTAIN ERRORS** Comprehensive analysis of FloodLAMP's October 2021 FDA correspondence sequence, synthesizing the full email thread, FDA deficiency letter, meeting notes, and final deprioritization decision, with background from FDA town hall transcripts, open EUA context, and the AI deprioritization research report. Includes factual timeline summary and five interpretive explanations of FDA's rationale. fda-correspondence, deprioritization, eua, quickcolor, october-2021, open-protocol md CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/ 6447 9443 gfile-url xfile-github-download-url pdf-gdrive-url pdf-github-url github-markdown-url github-markdown-download-url web-pdf-url web-slides-url youtube-url web-url